Cyclerion Therapeutics Overview
Cyclerion Therapeutics (CYCN) has a ROE of -131.85%, below the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow-131.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cyclerion Therapeutics (CYCN) currently reports a ROE of -131.85%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Cyclerion Therapeutics's ROE history and peer comparisons.
Cyclerion Therapeutics's ROE of -131.85% is lower than the Healthcare sector average of 22.01%. That is roughly 699.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cyclerion Therapeutics's current -131.85% should be judged against Healthcare norms (sector average: 22.01%) and against CYCN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -131.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Cyclerion Therapeutics, and consider following CYCN for alerts when major investors trade the stock.
Cyclerion Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -131.85% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYCN with unrelated industries.
